OLUWADARA OSINUBI: Open Payments
NPI 1134756794 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$975 in 36 payments from 7 companies in 2025. Trend: 2023 $350 · 2024 $394 · 2025 $975
Food & beverage: $975
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $441 |
| ABBVIE INC. | 8 | $177 |
| Otsuka America Pharmaceutical, Inc. | 5 | $133 |
| Alkermes, Inc. | 6 | $122 |
| Lundbeck LLC | 3 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: INGREZZA, VRAYLAR, ARISTADA, ABILIFY ASIMTUFII, REXULTI, ABILIFY MAINTENA, CAPLYTA, LYBALVI.
Industry payments across MD — which companies pay providers there.
